Luna Mora-Huerta

Luna Mora-Huerta

Auto-generated profile, based on publicly available information

Luna Mora-Huerta

Laboratory of Comparative and Regenerative Neurobiology, Cavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia, Paterna, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
LILeire Izagirre-Urizar
Leire Izagirre-Urizar
LMLuna Mora-Huerta
Luna Mora-Huerta
ISIrene Soler-Saez
Irene Soler-Saez
RMRaquel Morales-Gallel
Raquel Morales-Gallel
MUMaria-Jose Ulloa-Navas
Maria-Jose Ulloa-Navas
T Vanja Tepavcevic
Vanja Tepavcevic
Neurodegenerative pathologies including multiple sclerosis (MS) are consistently associated with energy deficit in the central nervous system (CNS). This might directly impact myelinating oligodendrocytes as these are particularly vulnerable to metabolic insults. Importantly, oligodendroglial dysfunction and myelin alterations occur in most, if not all neurodegenerative diseases, and are associated with axonal pathology/loss. Thus, elucidating metabolic mechanisms required for oligodendroglial myelin maintenance and axonal support might be crucial to identify therapeutic targets to achieve neuroprotection. While monocarboxylates are important energy fuels for the CNS, their role in myelinating oligodendrocyte function remains unclear. Here we show that, just like neurons, myelinating oligodendrocytes express high affinity monocarboxylate transporter 2 (MCT2) both in mice and humans, which is downregulated in progressive MS. While deletion of MCT2 in mouse oligodendrocytes did not affect the survival of these cells, it resulted in downregulation of lipid synthesis-associated enzymes and failure of myelin maintenance. Moreover, axonal upregulation of lactate dehydrogenase A concomitant with axonal damage was observed but could be alleviated by ketogenic diet. We conclude that oligodendroglial MCT2 is required for myelin maintenance and axonal support, which becomes altered in progressive MS, but may be compensated for by specific metabolic therapies. Graphical

18 June 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
LILeire Izagirre-Urizar
Leire Izagirre-Urizar
LMLuna Mora-Huerta
Luna Mora-Huerta
ISIrene Soler-Saez
Irene Soler-Saez
RMRaquel Morales-Gallel
Raquel Morales-Gallel
MMMary-Amélie Masson
Mary-Amélie Masson
T Vanja Tepavcevic
Vanja Tepavcevic
Myelin alterations, tightly linked to axonal degeneration, are common in neurodegenerative diseases, including multiple sclerosis (MS). However, the metabolic mechanisms that sustain white matter integrity remain elusive. Monocarboxylates are important energy fuels, but their role in myelinating oligodendrocyte function remains unclear. Here, we show that myelinating oligodendrocytes express high affinity monocarboxylate transporter 2 (MCT2), which is downregulated in progressive MS. While deletion of MCT2 in the mouse spinal white matter using oligodendrotropic AAV injection does not affect oligodendrocyte survival, it downregulates lipid synthesis-associated enzymes and increases inflammation, leading to a failure of myelin maintenance. These changes, not evidenced in AAV-control mice that only show mild inflammation, are accompanied by axonal upregulation of lactate dehydrogenase A and injury, effects alleviated by ketogenic diet. Therefore, our findings show that oligodendroglial MCT2 regulates myelin maintenance and axonal support under mild inflammation. This appears disrupted in progressive MS but might be compensated for by specific metabolic therapies to preserve white matter integrity.